Vitrectomy (Pars Plana Vitrectomy) — Cost, Top Hospitals & Success Rates | MyMedicPlus

Pars plana vitrectomy (PPV) is a microsurgical procedure in which the vitreous gel filling the posterior segment of the eye is removed and the retina is treated under direct visualisation. First described by Robert Machemer in 1971, modern vitrectomy has undergone transformative miniaturisation: contemporary systems use 23-gauge, 25-gauge, or 27-gauge transconjunctival self-sealing cannulae that are inserted through the pars plana (a surgically safe zone 3.5–4 mm posterior to the limbus) without the need for sutures in most cases.

During the procedure, the vitreous gel is excised using a pneumatic vitreous cutter that simultaneously cuts and aspirates the vitreous at rates of up to 10,000 cuts per minute, replacing it with an infusion of balanced salt solution (BSS) to maintain intraocular pressure. The retina can then be treated with endolaser photocoagulation, membrane peeling, subretinal fluid drainage, or injection of tamponade agents.

The choice of tamponade agent depends on the pathology:

• Air: Short-acting (reabsorbed in 5–7 days); used for simple macular hole closure.
• Sulfur hexafluoride (SF6): Expansile gas lasting 10–14 days; preferred for rhegmatogenous retinal detachment with small to moderate breaks.
• Perfluoropropane (C3F8): Long-acting gas lasting 6–8 weeks; used for macular holes and superior breaks requiring prolonged tamponade.
• Silicone oil: Permanent (requires surgical removal at 3–6 months); reserved for complex cases including proliferative vitreoretinopathy (PVR), giant retinal tears, and traumatic retinal detachment where gas reabsorption would occur before adequate healing.

Vitrectomy is a highly specialised procedure requiring a trained vitreoretinal surgeon and a dedicated operating microscope with wide-angle viewing systems (Binocular Indirect Ophthalmomicroscope, BIOM).

Vitrectomy is the definitive surgical treatment for a wide range of sight-threatening posterior segment conditions:

• Rhegmatogenous retinal detachment (RRD): Separation of the neurosensory retina from the retinal pigment epithelium through a tear or break. PPV with endotamponade has largely replaced scleral buckling as the primary surgical approach in phakic and pseudophakic eyes, with anatomical success rates exceeding 90% for primary surgery.
• Macular hole: A full-thickness defect in the centre of the macula causing central scotoma and metamorphopsia. PPV with internal limiting membrane (ILM) peeling and gas tamponade achieves closure rates of 90–98% for stage 2–4 macular holes.
• Vitreous haemorrhage: Blood obscuring the vitreous cavity from diabetic retinopathy (new vessel rupture), retinal vein occlusion, trauma, or posterior vitreous detachment with associated retinal tear. Vitrectomy clears the haemorrhage and allows treatment of the underlying cause.
• Epiretinal membrane (ERM): A fibrocellular proliferative membrane on the inner retinal surface causing metamorphopsia and reduced visual acuity. PPV with ERM and ILM peeling removes the contractile membrane and improves or stabilises vision in the majority of patients.
• Diabetic tractional retinal detachment (TRD): Fibrovascular membranes in proliferative diabetic retinopathy pull the retina off the RPE. Vitrectomy with membrane dissection or segmentation detaches the tractional forces and allows retinal reapposition.
• Endophthalmitis: Severe intraocular bacterial or fungal infection. Emergency vitrectomy combined with intravitreal antibiotics is indicated for severe post-operative or post-traumatic endophthalmitis, as vitrectomy significantly improves visual outcomes compared with vitreous tap and injection alone.
• Dropped nucleus or dislocated intraocular lens (IOL): Vitrectomy is required to retrieve a posteriorly displaced crystalline lens nucleus or dislocated IOL safely from the vitreous cavity.

Eligibility for vitrectomy is based on the underlying diagnosis, visual potential of the eye, systemic factors, and patient-specific considerations:

Ophthalmic Assessment

• Best-corrected visual acuity (BCVA) and visual potential are assessed; vitrectomy for macular conditions provides the best outcomes when the central photoreceptors are structurally intact on optical coherence tomography (OCT).
• OCT imaging is essential for macular holes (staging), ERM assessment, and sub-macular fluid in RRD. Wide-field fundus photography and fluorescein angiography delineate the extent of retinal pathology.
• B-scan ultrasonography is performed when the fundal view is obscured by vitreous haemorrhage or dense cataract to confirm retinal attachment and exclude other pathology.
• Lens status: Phakic patients (natural lens present) should be counselled that cataract formation within 1–2 years of vitrectomy is very common, particularly in older patients. Combined phacoemulsification and vitrectomy (phacovitrectomy) is frequently offered to patients over 50 who have visually significant lens changes, eliminating the need for a second procedure.

Systemic Considerations

• Patients on anticoagulant or antiplatelet therapy require individualised risk-benefit assessment; most agents are continued for routine vitrectomy, as sub-retinal haemorrhage risk from stopping anticoagulation typically outweighs bleeding risk.
• Patients with insulin-dependent diabetes require perioperative blood glucose management to reduce infection risk.
• Absolute contraindication to gas tamponade: patients who require nitrous oxide anaesthesia (which expands intraocular gas), patients who need air travel within 8 weeks of surgery, or patients unable to maintain the required post-operative positioning.

Modern vitrectomy technique is customised to the specific diagnosis, with several key surgical decisions made by the operating vitreoretinal surgeon:

Gauge Selection

• 23-gauge: Widely used; balanced between instrument rigidity and wound size. Requires suturing of sclerotomies in some cases. Preferred for complex, prolonged cases.
• 25-gauge: The dominant system in contemporary practice; fully transconjunctival and self-sealing in most cases. Offers excellent illumination and instrument options.
• 27-gauge: Smallest calibre; minimal trauma, virtually always sutureless. Optimal for macular surgery (ILM peeling, ERM peeling) where fine instrument control is paramount. Less suitable for cases requiring heavy-duty instrument use.

Phacovitrectomy

Combined phacoemulsification cataract extraction with posterior chamber IOL implantation and vitrectomy in a single session. Preferred in patients over 50 with any lens opacity, as vitrectomy accelerates nuclear sclerosis and a second procedure within 1–2 years is otherwise highly likely.

Membrane Peeling Techniques

Epiretinal membranes and the internal limiting membrane (ILM) are peeled using fine-gauge forceps under the operating microscope. Vital dyes — brilliant blue G (BBG) for ILM staining and triamcinolone acetonide to visualise the vitreous cortex — dramatically improve the safety and completeness of membrane peeling.

Endolaser Photocoagulation

Applied intraoperatively via an endolaser probe to create chorioretinal adhesion around retinal breaks, areas of ischaemia in diabetic retinopathy, or the margins of a detached retina after reattachment.

Tamponade Selection by Indication

• Simple RRD (inferior or superior break, no PVR): SF6 gas for 10–14 days.
• Macular hole: C3F8 gas with prone positioning for 5–7 days.
• Complex RRD with PVR, giant tear, or inferior break: Silicone oil for 3–6 months, then oil removal surgery.
• Trauma or diabetic TRD: Silicone oil in eyes with poor compliance, monocular patients, or where prolonged tamponade is required.

Vitrectomy offers definitive treatment for conditions that would otherwise result in permanent visual loss:

• High anatomical success for retinal detachment: Primary vitrectomy achieves retinal reattachment in over 90% of rhegmatogenous retinal detachments in a single procedure, with final reattachment rates after re-operation exceeding 98% at most vitreoretinal centres.
• Excellent macular hole closure rates: Modern small-gauge vitrectomy with ILM peeling and gas tamponade closes macular holes in 90–98% of cases, with most patients experiencing meaningful improvement in visual acuity within 3–6 months of surgery.
• Vision preservation in vitreous haemorrhage: Clearing dense vitreous blood allows retinal treatment (laser for diabetic neovascularisation) and rapid visual rehabilitation rather than waiting months for spontaneous haemorrhage resolution.
• Rapid visual recovery with small-gauge systems: The sutureless 25- and 27-gauge techniques cause minimal conjunctival and scleral disruption, significantly reducing post-operative inflammation, astigmatism, and discomfort. Patients typically experience vision improvement within days to weeks.
• Treatment of multiple pathologies in a single session: Combined phacovitrectomy, membrane peeling, laser, and tamponade can be delivered in a single anaesthetic episode, reducing the cumulative risk and inconvenience of multiple separate procedures.
• Life-saving in endophthalmitis: Prompt vitrectomy for severe endophthalmitis dramatically improves visual outcomes compared with intravitreal antibiotics alone, particularly when initial visual acuity is light perception or worse.

Vitrectomy is performed within the closed space of the eye and carries specific intraocular risks in addition to those common to all surgery:

Intraoperative Complications

• Iatrogenic retinal break: Instrument contact with the peripheral retina may create new tears during vitrectomy. These are treated immediately with endolaser. Rate is approximately 5–10% and most are treated definitively intraoperatively.
• Choroidal haemorrhage: Expulsive or sub-choroidal bleeding during surgery is rare but sight-threatening; risk is highest in patients on anticoagulation and in eyes with high myopia.

Post-Operative Complications

• Cataract formation: The most common long-term complication in phakic patients. Vitrectomy disrupts the oxygen environment of the vitreous, accelerating nuclear sclerosis. Clinically significant cataract develops in approximately 60–80% of phakic patients within 2 years of vitrectomy, typically requiring phacoemulsification.
• Elevated intraocular pressure (IOP): Gas tamponade causes transient IOP elevation in 20–30% of patients, usually in the first 24–48 hours. Managed with topical anti-glaucoma drops or systemic acetazolamide. Persistent glaucoma is uncommon.
• Retinal re-detachment: Re-detachment after initially successful primary vitrectomy occurs in approximately 5–10% of cases and is more common in eyes with PVR. Re-operation with silicone oil tamponade is typically required.
• Endophthalmitis: Post-vitrectomy intraocular infection occurs in approximately 0.03–0.08% of cases. Presents with pain, redness, and rapid vision loss within days of surgery. Emergency vitreous tap with intravitreal antibiotics is required immediately.
• Macular pucker (ERM) recurrence: After ERM peeling, recurrence of a new epiretinal membrane occurs in approximately 5–10% of patients within 5 years.
• Silicone oil complications: Oil migration into the anterior chamber can cause band keratopathy; oil emulsification leads to secondary glaucoma and cataract. Silicone oil must be removed surgically, usually at 3–6 months after surgery.
• Sympathetic ophthalmia: Extremely rare (estimated 0.01%) inflammatory condition affecting the fellow eye after vitreoretinal surgery, mediated by an immune response to uveal antigens.

Post-operative care after vitrectomy is active and requires careful compliance from the patient, particularly regarding positioning and activity restrictions during the tamponade phase.

Immediate Post-Operative Period

• Patients are reviewed the morning after surgery for IOP check, anterior segment assessment (look for gas bubble overfill, IOP spike), and wound integrity. Topical antibiotic and steroid eye drops are prescribed for 4–6 weeks.
• Positioning requirements: For macular hole repair, strict face-down (prone) positioning for 5–7 days post-operatively maintains gas tamponade contact with the foveal defect and maximises closure rates. Positioning is unnecessary for peripheral retinal detachments when gas fills the superior retina adequately in an upright posture.
• Pain is typically mild and managed with paracetamol. Significant pain should prompt urgent review to exclude IOP spike or endophthalmitis.

Activity and Travel Restrictions

• Patients with intraocular gas must not travel by air or ascend to high altitude until the gas bubble has fully reabsorbed, as reduced atmospheric pressure causes gas expansion and can raise IOP to dangerous levels. This restriction typically applies for 6–8 weeks with C3F8 gas.
• Patients receiving nitrous oxide anaesthesia for any other surgery during the gas period must inform their anaesthetist, as nitrous oxide diffuses into the gas bubble and causes dangerous expansion.

Follow-Up Schedule

• Day 1: IOP and anterior segment check; wound assessment.
• 1–2 weeks: Gas bubble level assessment; visual acuity; retinal examination.
• 4–6 weeks: After gas reabsorption — fundal examination, OCT for macular hole closure, review of diabetic or vascular pathology laser coverage.
• 3 months: Final visual outcome assessment; cataract evaluation in phakic patients; IOP surveillance.
• Silicone oil cases: Scheduled oil removal surgery at 3–6 months with assessment of retinal attachment before removal.

The cost of vitrectomy varies significantly based on multiple factors related to the complexity of the procedure and the healthcare environment:

• Diagnosis and surgical complexity: A straightforward macular hole repair with 25-gauge vitrectomy and air tamponade is far less expensive than a complex diabetic tractional retinal detachment involving lengthy membrane dissection and silicone oil placement. Complexity directly correlates with operating time and consumable use.
• Gauge system and disposable instruments: Each 25-gauge or 27-gauge trocar-cannula system, light pipe, vitreous cutter, and associated tubing is a single-use sterile disposable. The per-case cost of these consumables ranges from USD 500 to USD 2,000 depending on the system and instrument set used.
• Tamponade agent: Intraocular gas (SF6, C3F8) is relatively inexpensive. Medical-grade silicone oil adds several hundred dollars to procedure cost and also requires a second oil-removal procedure at 3–6 months.
• Pharmacological adjuncts: Intravitreal anti-VEGF injection (bevacizumab, ranibizumab, aflibercept) administered at the time of surgery for diabetic vitrectomy adds USD 50–2,000 depending on the agent used. Brilliant blue G dye, triamcinolone acetonide, and perfluorocarbon liquid are additional consumables in complex cases.
• Combined phacovitrectomy: Adding cataract surgery increases cost but is cost-effective compared with two separate procedures.
• Country and facility: In the United States, vitrectomy costs range from approximately USD 5,000 to USD 20,000 including surgeon fees, facility charges, and anaesthesia. In India, Thailand, or Southeast Asia, equivalent procedures at accredited vitreoretinal centres range from USD 800 to USD 4,000.

Several non-vitrectomy treatments exist for specific vitreoretinal conditions, and the choice between vitrectomy and alternatives depends on diagnosis, extent of disease, and patient factors:

Scleral Buckling

Placement of a silicone band or buckle around the equator of the eye indents the sclera to close retinal breaks and support the retinal detachment. Scleral buckling remains the preferred primary surgical option in young phakic patients with inferior detachments and simple breaks, as it avoids cataract formation and has excellent long-term outcomes in this demographic. Vitrectomy is preferred for pseudophakic patients, posterior breaks, and complex detachments.

Pneumatic Retinopexy

An outpatient procedure in which an expansile gas bubble is injected into the vitreous cavity through the office, combined with cryotherapy or laser to seal the responsible retinal break. Success rates of 70–80% for appropriately selected cases (single superior break, no PVR) with the advantage of no operating room requirement. Not suitable for inferior breaks, multiple breaks in different quadrants, or cases with significant PVR.

Laser Photocoagulation

Retinal laser (argon or diode) applied to retinal tears without associated detachment prevents progression to full detachment in approximately 90–95% of cases. Laser is also the definitive treatment for proliferative diabetic retinopathy and branch retinal vein occlusion with ischaemia, reducing the indication for vitrectomy by preventing the complications (neovascularisation, haemorrhage) that lead to vitrectomy referral.

Intravitreal Anti-VEGF Injections

For proliferative diabetic retinopathy without significant tractional retinal detachment, serial anti-VEGF injections (bevacizumab, ranibizumab, aflibercept) can regress neovascularisation and clear vitreous haemorrhage in many patients, deferring or avoiding vitrectomy. Anti-VEGF is also used as a pre-operative adjunct to reduce intraoperative bleeding during diabetic vitrectomy.

Observation

Small vitreous haemorrhages without retinal detachment may clear spontaneously over weeks to months. Observation with serial B-scan ultrasonography is appropriate when no retinal detachment is present and the patient understands the risk of delayed treatment.